These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20739906)

  • 1. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.
    Kaspera R; Naraharisetti SB; Tamraz B; Sahele T; Cheesman MJ; Kwok PY; Marciante K; Heckbert SR; Psaty BM; Totah RA
    Pharmacogenet Genomics; 2010 Oct; 20(10):619-29. PubMed ID: 20739906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.
    Ishikawa C; Ozaki H; Nakajima T; Ishii T; Kanai S; Anjo S; Shirai K; Inoue I
    J Hum Genet; 2004; 49(10):582-585. PubMed ID: 15365880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerivastatin, genetic variants, and the risk of rhabdomyolysis.
    Marciante KD; Durda JP; Heckbert SR; Lumley T; Rice K; McKnight B; Totah RA; Tamraz B; Kroetz DL; Fukushima H; Kaspera R; Bis JC; Glazer NL; Li G; Austin TR; Taylor KD; Rotter JI; Jaquish CE; Kwok PY; Tracy RP; Psaty BM
    Pharmacogenet Genomics; 2011 May; 21(5):280-8. PubMed ID: 21386754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
    Wang JS; Neuvonen M; Wen X; Backman JT; Neuvonen PJ
    Drug Metab Dispos; 2002 Dec; 30(12):1352-6. PubMed ID: 12433802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.
    Kaspera R; Naraharisetti SB; Evangelista EA; Marciante KD; Psaty BM; Totah RA
    Biochem Pharmacol; 2011 Sep; 82(6):681-91. PubMed ID: 21726541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.
    Ozaki H; Ishikawa CT; Ishii T; Toyoda A; Murano T; Miyashita Y; Shirai K
    J Clin Pharm Ther; 2005 Apr; 30(2):189-92. PubMed ID: 15811174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.
    Shitara Y; Hirano M; Sato H; Sugiyama Y
    J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel.
    Floyd JS; Kaspera R; Marciante KD; Weiss NS; Heckbert SR; Lumley T; Wiggins KL; Tamraz B; Kwok PY; Totah RA; Psaty BM
    Clin Pharmacol Ther; 2012 May; 91(5):896-904. PubMed ID: 22419147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.
    Tamraz B; Fukushima H; Wolfe AR; Kaspera R; Totah RA; Floyd JS; Ma B; Chu C; Marciante KD; Heckbert SR; Psaty BM; Kroetz DL; Kwok PY
    Pharmacogenet Genomics; 2013 Jul; 23(7):355-64. PubMed ID: 23652407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population.
    Hichiya H; Tanaka-Kagawa T; Soyama A; Jinno H; Koyano S; Katori N; Matsushima E; Uchiyama S; Tokunaga H; Kimura H; Minami N; Katoh M; Sugai K; Goto Y; Tamura T; Yamamoto N; Ohe Y; Kunitoh H; Nokihara H; Yoshida T; Minami H; Saijo N; Ando M; Ozawa S; Saito Y; Sawada J
    Drug Metab Dispos; 2005 May; 33(5):630-6. PubMed ID: 15716363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.
    Hanioka N; Matsumoto K; Saito Y; Narimatsu S
    Basic Clin Pharmacol Toxicol; 2010 Jul; 107(1):565-9. PubMed ID: 20148860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.
    Kazmi F; Barbara JE; Yerino P; Parkinson A
    Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes.
    Bahadur N; Leathart JB; Mutch E; Steimel-Crespi D; Dunn SA; Gilissen R; Houdt JV; Hendrickx J; Mannens G; Bohets H; Williams FM; Armstrong M; Crespi CL; Daly AK
    Biochem Pharmacol; 2002 Dec; 64(11):1579-89. PubMed ID: 12429347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
    Tsukada C; Saito T; Maekawa M; Mano N; Oda A; Hirasawa N; Hiratsuka M
    Drug Metab Pharmacokinet; 2015 Oct; 30(5):366-73. PubMed ID: 26427316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.
    Lai XS; Yang LP; Li XT; Liu JP; Zhou ZW; Zhou SF
    Curr Drug Metab; 2009 Nov; 10(9):1009-47. PubMed ID: 20214592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
    Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
    Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
    Psaty BM; Furberg CD; Ray WA; Weiss NS
    JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.
    Taniguchi R; Kumai T; Matsumoto N; Watanabe M; Kamio K; Suzuki S; Kobayashi S
    J Pharmacol Sci; 2005 Jan; 97(1):83-90. PubMed ID: 15655291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.
    Dai D; Zeldin DC; Blaisdell JA; Chanas B; Coulter SJ; Ghanayem BI; Goldstein JA
    Pharmacogenetics; 2001 Oct; 11(7):597-607. PubMed ID: 11668219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of splice variants of human cytochrome P450 2C8 (CYP2C8) to mitochondria and their role in arachidonic acid metabolism and respiratory dysfunction.
    Bajpai P; Srinivasan S; Ghosh J; Nagy LD; Wei S; Guengerich FP; Avadhani NG
    J Biol Chem; 2014 Oct; 289(43):29614-30. PubMed ID: 25160618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.